CN105492461B - 结合人类补体因子c2的结合分子及其应用 - Google Patents

结合人类补体因子c2的结合分子及其应用 Download PDF

Info

Publication number
CN105492461B
CN105492461B CN201480042146.0A CN201480042146A CN105492461B CN 105492461 B CN105492461 B CN 105492461B CN 201480042146 A CN201480042146 A CN 201480042146A CN 105492461 B CN105492461 B CN 105492461B
Authority
CN
China
Prior art keywords
seq
antibody
human
binding molecule
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480042146.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105492461A (zh
Inventor
C·E·哈克
C·伊尔迪兹
L·波恩
P·J·西蒙斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BROTEIO PHARMA BV
Original Assignee
BROTEIO PHARMA BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BROTEIO PHARMA BV filed Critical BROTEIO PHARMA BV
Publication of CN105492461A publication Critical patent/CN105492461A/zh
Application granted granted Critical
Publication of CN105492461B publication Critical patent/CN105492461B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480042146.0A 2013-05-23 2014-05-22 结合人类补体因子c2的结合分子及其应用 Active CN105492461B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13168941 2013-05-23
EP13168941.6 2013-05-23
PCT/NL2014/050327 WO2014189378A1 (en) 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2 and uses thereof

Publications (2)

Publication Number Publication Date
CN105492461A CN105492461A (zh) 2016-04-13
CN105492461B true CN105492461B (zh) 2019-11-26

Family

ID=48485015

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480042146.0A Active CN105492461B (zh) 2013-05-23 2014-05-22 结合人类补体因子c2的结合分子及其应用

Country Status (14)

Country Link
US (2) US9944717B2 (https=)
EP (2) EP2999714B1 (https=)
JP (3) JP2016520313A (https=)
CN (1) CN105492461B (https=)
AU (1) AU2014269193C1 (https=)
CA (1) CA2913318C (https=)
DK (2) DK3725803T3 (https=)
ES (2) ES2904709T3 (https=)
HU (2) HUE049769T2 (https=)
LT (2) LT2999714T (https=)
MX (1) MX366046B (https=)
PL (2) PL3725803T3 (https=)
PT (2) PT3725803T (https=)
WO (1) WO2014189378A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
CN105492461B (zh) * 2013-05-23 2019-11-26 布罗泰欧制药有限公司 结合人类补体因子c2的结合分子及其应用
HUE073475T2 (hu) * 2016-10-12 2026-01-28 Bioverativ Usa Inc C1s elleni antitestek és alkalmazási eljárásaik
WO2020121282A1 (en) * 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use
GB2584105B (en) 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
WO2021026609A1 (en) * 2019-08-12 2021-02-18 CSL Innovation Pty Ltd Complement c2 binding proteins and uses thereof
AU2023210793A1 (en) * 2022-01-29 2024-06-06 Kira Pharmaceuticals (Suzhou) Ltd. Anti-c2 antibodies and uses thereof
GB202407051D0 (en) 2024-05-17 2024-07-03 argenx BV Methods of treating osteoarthritis pain
WO2025257157A1 (en) 2024-06-10 2025-12-18 argenx BV Treatment or prevention of ischemia reperfusion injury in organ tranplantation
WO2025260123A1 (en) * 2024-06-17 2025-12-26 CSL Innovation Pty Ltd Anti-c2 antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070818A1 (en) * 2000-03-23 2001-09-27 Tanox, Inc. Anti-c2/c2a inhibitors of complement activation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
CN105492461B (zh) 2013-05-23 2019-11-26 布罗泰欧制药有限公司 结合人类补体因子c2的结合分子及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070818A1 (en) * 2000-03-23 2001-09-27 Tanox, Inc. Anti-c2/c2a inhibitors of complement activation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Complement C2 siRNA mediated therapy of myasthenia gravis in mice;Ruksana Huda et al.;《Complement C2 siRNA mediated therapy of myasthenia gravis in mice》;20130501;第42卷;94-104 *

Also Published As

Publication number Publication date
JP2020007318A (ja) 2020-01-16
ES2904709T3 (es) 2022-04-05
LT2999714T (lt) 2020-07-10
HUE049769T2 (hu) 2020-10-28
US10717785B2 (en) 2020-07-21
AU2014269193C1 (en) 2020-02-20
US9944717B2 (en) 2018-04-17
DK2999714T3 (da) 2020-06-02
PL2999714T3 (pl) 2020-10-19
EP2999714B1 (en) 2020-04-01
US20180319895A1 (en) 2018-11-08
MX2015016120A (es) 2016-10-28
CN105492461A (zh) 2016-04-13
HUE057858T2 (hu) 2022-06-28
PT3725803T (pt) 2021-12-24
MX366046B (es) 2019-06-26
JP7414929B2 (ja) 2024-01-16
LT3725803T (lt) 2022-03-10
JP2016520313A (ja) 2016-07-14
CA2913318A1 (en) 2014-11-27
EP3725803A1 (en) 2020-10-21
AU2014269193A1 (en) 2015-12-17
JP2023002684A (ja) 2023-01-10
WO2014189378A1 (en) 2014-11-27
CA2913318C (en) 2024-03-26
AU2014269193B2 (en) 2019-08-15
ES2784616T3 (es) 2020-09-29
PT2999714T (pt) 2020-04-30
HK1223385A1 (zh) 2017-07-28
US20160108134A1 (en) 2016-04-21
EP3725803B1 (en) 2021-12-15
EP2999714A1 (en) 2016-03-30
DK3725803T3 (da) 2022-03-07
PL3725803T3 (pl) 2022-04-04
JP7163254B2 (ja) 2022-10-31

Similar Documents

Publication Publication Date Title
CN105492461B (zh) 结合人类补体因子c2的结合分子及其应用
JP6783754B2 (ja) 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体
JP2014530188A (ja) Ｐｃｓｋ９に対する抗体およびその使用
KR20140019375A (ko) 인간 조직 인자 항체 및 이의 용도
CN105705517A (zh) 用于治疗凝血障碍的新方法和抗体
JP2020115863A (ja) 改良された血液凝固促進抗体
CN105473619B (zh) 能够引起促凝血活性的识别组织因子途径抑制剂的n-末端部分的抗体
EP4444758A2 (en) Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
HK1223385B (zh) 结合人类补体因子c2的结合分子及其应用
JP7754841B2 (ja) ヒト化抗ヒトｃｄ８９抗体及びその使用
TW201617371A (zh) 針對經活化之因子ｖ之抗體
EA051993B1 (ru) Гуманизированные антитела к cd89 человека и варианты их применения
HK40121588A (zh) 针对人补体因子c2b的抗体及使用方法
HK40050349B (zh) 针对人补体因子c2b的抗体及使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1223385

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant